Mindray is a leading global provider of medical devices and healthcare solutions, headquartered in Shenzhen, China. The company focuses on the research, development, manufacturing, marketing and service of medical technologies, with three core business segments: Patient Monitoring & Life Support, In Vitro Diagnostics, and Medical Imaging. Its product portfolio covers a broad range of clinical applications, while its emerging businesses include animal medical care, minimally invasive surgery and automated external defibrillators (AEDs). Mindray has established a global R&D, marketing and service network, with products sold in more than 190 countries and regions.

Mindray combines medical technology, digitalisation and artificial intelligence to develop integrated healthcare solutions. The company is advancing its “Equipment + IT + AI” healthcare ecosystem and has established a global R&D network spanning China, the United States, Finland and Germany. In 2025, Mindray invested RMB 3.929 billion in R&D and had more than 5,200 R&D engineers. It also launched “Project 2030” to expand medical education and professional training through ultrasound training schools and academic exchange programmes.

In terms of sustainability, Mindray integrates ESG principles into innovation, operations, supply-chain management, employee development and social responsibility. Its 2025 Sustainability Report, published in March 2026, was prepared with reference to the Shenzhen Stock Exchange Sustainability Reporting Guidelines, GRI Standards and the UN Sustainable Development Goals. The company has set a target to reduce carbon-emission intensity by 25% by 2030 from the 2021 baseline; by 2025, its carbon-emission intensity had decreased by 9.1% from the baseline. Mindray has also promoted energy efficiency, green manufacturing and product carbon-footprint management, with nine products receiving carbon-footprint certification. Its 2025 ESG performance was recognised by an MSCI ESG rating of AA, an EcoVadis Silver Medal and a CDP Climate Change score of B.

迈瑞医疗是全球领先的医疗器械及解决方案供应商，总部位于中国深圳，主要从事医疗器械的研发、制造、营销及服务，核心业务覆盖生命信息与支持、体外诊断、医学影像三大领域，并布局动物医疗、微创外科及自动体外除颤器（AED）等新兴业务。公司已建立全球化研发、营销及服务网络，产品销往全球190多个国家和地区。

迈瑞医疗将医疗科技、数字化与人工智能相结合，持续推进“设备+IT+AI”智慧医疗生态建设，并建立覆盖中国、美国、芬兰、德国等地的全球研发体系。2025年，公司研发投入达39.29亿元，拥有超过5,200名研发工程师；同时启动“Project 2030（2030行动）”，通过建设超声培训学校、开展学术交流等方式推动医疗专业能力建设和优质医疗资源普及。

在可持续发展方面，迈瑞医疗将ESG理念融入科技创新、绿色运营、供应链管理、员工发展及社会责任等领域。公司于2026年3月发布《2025年度可持续发展报告》，报告参考深交所《上市公司可持续发展报告指引》、GRI标准及联合国可持续发展目标等框架编制。公司承诺到2030年将碳排放强度较2021年基准降低25%，截至2025年碳排放强度已较基准下降9.1%；同时持续推进节能降耗、绿色制造及产品碳足迹管理，已有9项产品获得碳足迹认证。2025年，公司获得MSCI ESG评级AA、EcoVadis银牌，并在CDP气候变化问卷中获得B级评价。